Gellér L - Search Results

1

The impact of cardiac resynchronization therapy on routine laboratory parameters.

Boros AM, Perge P, Nagy KV, Apor A, Bagyura Z, Zima E, Molnár L, Tahin T, Becker D, Gellér L, Merkely B, Széplaki G. Boros AM, et al. Among authors: geller l. Interv Med Appl Sci. 2017 Mar;9(1):1-8. doi: 10.1556/1646.9.2017.1.01. Interv Med Appl Sci. 2017. PMID: 28932489 Free PMC article.

2

Electrophysiological effects of intrapericardial infusion of endothelin-1.

Gellér L, Merkely B, Szokodi I, Szabó T, Vecsey T, Juhász-Nagy A, Tóth M, Horkay F. Gellér L, et al. Pacing Clin Electrophysiol. 1998 Jan;21(1 Pt 2):151-6. doi: 10.1111/j.1540-8159.1998.tb01079.x. Pacing Clin Electrophysiol. 1998. PMID: 9474663

3

Verapamil reduces the arrhythmogenic effect of endothelin.

Solti F, Tóth M, Merkely B, Kékesi V, Gellér L, Szokodi I, Horkay F, Juhász-Nagy A. Solti F, et al. Among authors: geller l. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S386-7. doi: 10.1097/00005344-199800001-00110. J Cardiovasc Pharmacol. 1998. PMID: 9595491

4

Potential pathophysiologic role of endothelin-1 in canine pericardial fluid.

Horkay F, Szokodi I, Merkely B, Solti F, Gellér L, Kiss P, Selmeci L, Horváth I, Kékesi V, Juhász-Nagy A, Tóth M. Horkay F, et al. Among authors: geller l. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S401-2. doi: 10.1097/00005344-199800001-00115. J Cardiovasc Pharmacol. 1998. PMID: 9595496

5

Increased monophasic action potential dispersion in endothelin-1-induced ventricular arrhythmias.

Gellér L, Merkely B, Lang V, Szabó T, Fazekas L, Kékesi V, Kiss O, Horkay F, Schaldach M, Tóth M, Juhász-Nagy A. Gellér L, et al. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S434-6. doi: 10.1097/00005344-199800001-00124. J Cardiovasc Pharmacol. 1998. PMID: 9595505

6

Intrapericardial infusion of endothelin-1 induces ventricular arrhythmias in dogs.

Szokodi I, Horkay F, Merkely B, Solti F, Gellér L, Kiss P, Selmeci L, Kékesi V, Vuolteenaho O, Ruskoaho H, Juhász-Nagy A, Tóth M. Szokodi I, et al. Among authors: geller l. Cardiovasc Res. 1998 May;38(2):356-64. doi: 10.1016/s0008-6363(98)00018-2. Cardiovasc Res. 1998. PMID: 9709396

7

Investigating the dual nature of endothelin-1: ischemia or direct arrhythmogenic effect?

Szabó T, Gellér L, Merkely B, Selmeci L, Juhász-Nagy A, Solti F. Szabó T, et al. Among authors: geller l. Life Sci. 2000 May 19;66(26):2527-41. doi: 10.1016/s0024-3205(00)00587-7. Life Sci. 2000. PMID: 10883731

8

Fundamental electrophysiological differences between low-dose intracoronary endothelin-1 infusion and myocardial ischemia revealed by multiple monophasic action potential recording.

Gellér L, Szabó T, Kiss O, Solti F, Juhász-Nagy A, Merkely B. Gellér L, et al. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S167-71. doi: 10.1097/00005344-200036051-00052. J Cardiovasc Pharmacol. 2000. PMID: 11078368

9

The selective endothelin-A-receptor antagonist LU 135.252 inhibits the direct arrhythmogenic action of endothelin-1.

Merkely B, Szabó T, Gellér L, Kiss O, Horkay F, Raschack M, Juhász-Nagy A. Merkely B, et al. Among authors: geller l. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S314-6. doi: 10.1097/00005344-200036051-00091. J Cardiovasc Pharmacol. 2000. PMID: 11078407

10

Endothelin-A-receptor antagonist LU 135.252 inhibits the formation of ventricular arrhythmias caused by intrapericardial infusion of endothelin-1.

Kiss O, Gellér L, Merkely B, Szabó T, Raschack M, Seres L, Zima E, Juhász-Nagy A, Horkay F. Kiss O, et al. Among authors: geller l. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S317-9. doi: 10.1097/00005344-200036051-00092. J Cardiovasc Pharmacol. 2000. PMID: 11078408

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

613 results

Search Page

Filters